



WEPL01 What is our goal?

Plenary Session

Venue: Session Room 1

Time: 08:45-10:55

Co-Chairs: Aaron Motsoaledi, Minister of Health, South Africa
Jane Philpott, Health Canada, Canada

Award Presentation: Prize for Excellence in Research Related to Children Affected by HIV

Prevention Equity: Uptake of Innovations in Testing, Prevention, Reducing Incidence

N.Phanuphak, Thai Red Cross AIDS Research Centre, Thailand

TB and Co-Infections: The Long Game

A.Pozniak, Chelsea and Westminster Hospital NHS Trust, United Kingdom

Toward an HIV Vaccine

L.Corey, Fred Hutchinson Cancer Research Center and Washington University, United States

Award Presentation: CIPHER Grant Programme

L.Bekker, Desmond Tutu HIV Centre, South Africa

Youth Focus: Adolescents at Risk and in the Lead

T.Makadzange, Harvard University, United States; M.Ighodaro, AIDS Vaccine Advocacy Coalition (AVAC), Nigeria

WEWS05 An Interactive Learning Event on Positive Health, Dignity and Prevention for Pregnant Women and Mothers Living with HIV

Community Workshop

Venue: Global Village Session Room 1

Time: 11:00-12:30

Level: Intermediate

Target audience: Peer educator, Activist, Community health worker

Seating limit: 320

Co-Facilitators: Aditi Sharma, Global Network of People Living with HIV (GNP+), United Kingdom
Martha Tholanah, Network of Zimbabwean Positive Women (NZPW+), Zimbabwe
Eunice Sinyemu, Network of Zambian People Living with HIV & AIDS (NZP+), Zambia
Florence Anam, The International Community of Women Living with HIV (ICW), Kenya
Jane Shepherd, Positive Action, United Kingdom

Recognition of the critical role communities play in ending vertical transmission of HIV is rising, yet investment in community interventions such as treatment literacy and peer support is falling. This workshop aims to mobilize community activists to use the latest guidelines to empower pregnant women and mothers living with HIV with the information they need to make choices about their health. Participants learn about the key messages from the latest prevention of mother to child transmission and infant-feeding guidelines, a new Treatment Literacy Tool developed by the Inter-Agency Task Team members and generate ideas to maximize the benefit of such tools. Participants also have the opportunity to share knowledge on how networks of people living with HIV are leading efforts to support pregnant women living with HIV and defending their rights.

Treatment literacy guide for pregnant women and mothers living with HIV

A.Sharma, Global Network of People Living with HIV (GNP+), United Kingdom

The President's Emergency Plan for AIDS Relief's "Anti-Prostitution Pledge" and the Impact on Sex Worker Health Programs: the Who, the What, and the How

Community Workshop

Venue: Global Village Session Room 2

Time: 11:00-12:30

Level: Intermediate

Target audience: Advocate, General healthcare / Social services provider

Seating limit: 110

Co-Facilitators: Beirne Roose-Snyder, Center for Health and Gender Equity, United States
Constance Nothando Mathe, SWEAT, South Africa
Grace Kamau, Kenya Sex Workers Alliance (KESWA), Kenya
Kholi Buthelezi, Sisonke, South Africa
Jasmine Tyler, Open Society Foundations, United States
Anne Gathumbi, Open Society Foundations, United States
Marlise Richter, Sonke Gender Justice, South Africa
Deon Haywood, Women With A Vision, United States

The U.S. government, through the President's Emergency Plan for AIDS Relief (PEPFAR), is a major donor to the global fight against HIV and its contribution has averted millions of HIV infections and enhanced the lives of people living with HIV/AIDS. However, confusion remains over PEPFAR's funding restrictions related to how sex workers may be engaged in HIV programs, as well as whether calling for the removal of criminal laws on sex work is permitted. This workshop aims to clarify what PEPFAR says about sex work, including what kinds of activities and services are prohibited by current funding restrictions. The aim is to build the capacity of sex workers, sex workers' rights advocates, and HIV service providers to design, implement, and advocate for effective, evidence-based HIV prevention programs.

Welcome and introduction

History and current status of PEPFAR funding restrictions

Group discussion: how has the APLO affected your organization or work

Group work: best practices for programming that respect and protect sex workers' rights and developing advocacy strategies to advocate for effective programs and human rights

Report back from groups

Closing remarks

WEAC01 Making PrEP Real for Those Who Need It Most: Optimization Strategies

Oral Abstract Session

Venue: Session Room 1

Time: 11:00-12:30

Co-Chairs: LaRon Nelson, University of Toronto, Canada
Nyaradzo Mavis Mgodi, University of Zimbabwe, Zimbabwe

Introduction - video address

M.Touraine, Minister of Health and Social Affairs, France

Efficacy of on demand PrEP with TDF-FTC in the ANRS IPERGAY open-label extension study



J.-M. Molina, I. Charreau, B. Spire, L. Cotte, J. Chas, C. Capitant, C. Tremblay, D. Rojas-Castro, E. Cua, A. Pasquet, C. Bernaud, W. Rozenbaum, C. Delaunay, V. Doré, S. Le Mestre, M.-C. Simon, J.-F. Delfraissy, L. Meyer, ANRS IPERGAY Study Group
France

HPTN 073: successful engagement of Black MSM into a culturally relevant clinical trial for pre-exposure prophylaxis (PrEP)

C. Hucks-Ortiz, J.P. Lucas, D.P. Wheeler, S.D. Fields, The HPTN Black Caucus
United States

Correlates for levels of self-reported PrEP adherence among Black men who have sex with men in 3 U.S. cities

D. Wheeler, S. Fields, L. Nelson, L. Hightow-Weidman, M. Magnus, S. Shoptaw, G. Beauchamp, L. Emel, E. Piwowar-Manning, Y. Chen, P. Watkins, K. Mayer, HPTN073 Study Team
United States

Integrated delivery of PrEP and ART results in sustained near elimination of HIV transmission in African HIV serodiscordant couples: final results from The Partners Demonstration Project

J. Baeten, R. Heffron, L. Kidoguchi, N. Mugo, E. Katabira, E. Bukusi, S. Asiimwe, J. Morton, K. Ngure, N. Bulya, J. Odoyo, E. Tindimwemba, J. Haberer, M. Marzinke, D. Donnell, C. Celum
United States

SEARCH test and treat study in Uganda and Kenya exceeds the UNAIDS 90-90-90 cascade target by achieving 81% population-level viral suppression after 2 years

M. Petersen, L. Balzer, D. Kwarisima, N. Sang, G. Chamie, J. Ayieko, J. Kabami, A. Owaraganise, T. Liegler, F. Mwangwa, K. Kadede, V. Jain, A. Plenty, G. Lavoy, D. Black, E. Bukusi, C. Cohen, T. Clark, E. Charlebois, M. Kamya, D. Havlir, SEARCH Study Team
United States

Moderated discussion

WEAB01 Supporting Three Generations of Healthy Mothers and Healthy Babies

Oral Abstract Session

Venue: Session Room 4

Time: 11:00-12:30

Co-Chairs: Devasena Gnanashanmugam, National Institutes of Health, United States
Chewe Luo, UNICEF, United States

Acceptability of early HIV treatment among South African women

N. Garrett, E. Norman, V. Asari, N. Naicker, N. Majola, K. Leask, Q. Abdool Karim, S. Abdool Karim
South Africa

Timing of pregnancy among HIV-positive women, postpartum retention and risk of virologic failure

D. Onoya, T. Sineke, A. Brennan, M.P. Fox
South Africa

Adverse obstetrical outcomes among HIV-positive and HIV-negative mother-infant pairs in Nigeria and South Africa: findings from the INFANT study

P. Datong, H. Jaspán, S. Osawe, J. Gatei, J.-A. Coombs, K.A. Muldoon, R. Mallick, C. Gray, K. Rosenthal, D.W. Cameron, A. Abimiku
Nigeria

High proportion of deaths attributable to HIV among post-partum women in Botswana despite widespread uptake of ART

R. Zash, S. Souda, J. Leidner, K. Binda, C. Hick, K. Powis, J. Makhema, M. Mmalane, M. Essex, S. Lockman, R. Shapiro
United States

Birth weight and preterm delivery outcomes of perinatally vs. non-perinatally HIV-infected pregnant women in the U.S.: results from the PHACS SMARTT study and IMPAACT P1025 protocol

J. Jao, D. Kacanek, P. Williams, M. Geffner, E.G. Livingston, R.S. Sperling, K. Patel, A. Bardeguet, S. Burchett, N. Chakhtoura, G.B. Scott, R. Van Dyke, E.J. Abrams, Pediatric HIV/AIDS Cohort Study (PHACS) & International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network
United States

Moderated discussion

WEAE01 Innovations in HIV Testing: The First 90

Oral Abstract Session

Venue: Session Room 6

Time: 11:00-12:30

Co-Chairs: Andrew Boule, University of Cape Town, South Africa
Kwame Shanaube, ZAMBART Project, Zambia

Acceptability and preferences for HIV self-testing in Zambia: a population-based formative study using a discrete choice experiment

A. Zanolini, J. Chipungu, S. Bosomprah, M. Mafwenko, C. Holmes, H. Thirumurthy
Zambia

Benefits and adverse outcomes of HIV self-testing among high-risk MSM in China: an implementation perspective

Y. Qin, F. Liu, W. Tang, S. Tang, C. Liu, J. Mao, W. Zhang, A. Taege, A. Nowacki, C. Wei, J. Tucker
China

"Not without us?": views on the introduction of HIV self-testing among health care workers providing integrated HIV and sexual and reproductive health services

C. Madanhire, E. Sibanda, N. Ruhode, K. Hatzold, F.M. Cowan, S.N. Mavedzenge
Zimbabwe

Index client trailing: a home-based HIV counselling and testing strategy to identify and link people living with HIV to treatment

N. Manjezi, G. Fatti, E. Mothibi, N. Shaikh, O. Oyeibanji, A. Grimwood
South Africa

Results of a cluster-randomised trial of non-financial incentives to increase uptake of couples counselling and testing among clients attending PSI mobile HIV services in rural Zimbabwe

E.L. Sibanda, M. Tumushime, J. Mufuka, S. Gudukeya, S. Napierala Mavedzenge, S. Bautista-Arredondo, H. Thirumurthy, S. McCoy, N. Padian, K. Hatzold, A. Copas, F.M. Cowan
Zimbabwe

Reaching the first 90: improving coverage of inpatient pediatric provider-initiated HIV testing and counseling (PITC) using a quality improvement collaborative strategy at 24 health facilities in Tanzania

G. Dougherty, K. Clarke, R. Fayorsey, M. Kamonga, S. Kimambo, D. Lutkam, C. Madevu-Matson, H. Mtiro, S. Msuka, V. Mugisha, M. Panya, A. Ramadhani, J. Sipemba, P. Urasa, M. Rabkin
United States

WEAC02 Trans-forming HIV Prevention and Care Talk

Oral Abstract Session

Venue: Session Room 7

Time: 11:00-12:30

Co-Chairs: Leigh Ann van der Merwe, S.H.E. Social, Health And Empowerment Feminist Collective Of Transgender Women Of Africa, South Africa
Ayden I Scheim, Western University, Canada

Trans Nations: A Global Review

T. Poteat, Johns Hopkins University, United States

Transgender patients at risk: ensuring access to PrEP in a NYC community health centre

A. Radix, P. Carneiro, S. Stephanos, S. Mosher, P. Meacher, U. Belkind, I. Evans-Frantz, F. Brigham, A. Fortenberry, L. Comstock, R. Vail, S. Weiss, S. Pena, S. Golub
United States

LifeSkills: results from a full-scale, randomized controlled trial examining the efficacy of a group-based behavioural intervention for HIV prevention among young transgender women

R. Garofalo, L. Kuhns, S. Reisner, K. Biello, M. Mimiaga
United States

Differences between unknown HIV-positive and HIV-negative Black transgender women in the United States: results from Promoting Our Worth, Equality, and Resilience (POWER)

L. Bukowski, S. Meanley, J. Egan, D. Matthews, R. Stall, The Power Study Team



United States

Factors affecting HIV testing among transgender people in Ontario, Canada: results from a respondent-driven sampling survey

G.R. Bauer, M. Shokoohi, R. Hammond, A.I. Scheim
Canada

Moderated discussion

WEAA01 Acute HIV Infection: The Battle Begins

Oral Abstract Session

Venue: Session Room 8

Time: 11:00-12:30

Co-Chairs: Douglas Kwon, Ragon Institute of MGH, MIT and Harvard, United States
Tulio de Oliveira, University of KwaZulu-Natal, South Africa

Th17 cells are preferentially infected in the first 48 hours after vaginal transmission of SIVmac239 in macaques

D.J. Stieh, E. Matias, A.J. Fought, P.A. Marx, R.S. Veazey, T.J. Hope
United States

Effect of injectable hormonal contraceptives on vaginal epithelium thickness and genital HIV target cell density in women recently infected with HIV

S. Ngcapu, A.M. Carias, L.J. Liebenberg, L. Werner, G.C. Cianci, M. McRaven, S. Sibeko, N.J. Garrett, J.-M. Kriek, L.R. McKinnon, S. Abdool Karim, Q. Abdool Karim, J.-A.S. Passmore, T.J. Hope
South Africa

Characterization of early events of SIVagm dissemination following intrarectal inoculation in adult AGMs

K. Raetz, G. Haret-Richter, C. Ling Xu, B. Policicchio, C. Barrenas, D. Ma, V. Wijewardana, E. Brocca-Cofano, J. Stock, A. Trichel, B. Keele, J. Estes, M. Katze, I. Pandrea, C. Apetrei
United States

Early treatment of hyperacute HIV infection impacts phenotype and clonal repertoire of HIV-specific CD8+ T cells

Z. Ndhlovu, T. Nkosi, N. Mewalal, N. Ismail, A. Moodley, K. Dong, T. Ndu'ngu, B.D. Walker
United States

Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection

G.E. Martin, N. Pantazis, M. Hoffmann, S. Hickling, J. Hurst, J. Meyerowitz, C.B. Willberg, N. Robinson, H. Brown, M. Fisher, S. Kinloch, A. Babiker, J. Weber, N. Nwokolo, J. Fox, S. Fidler, R. Phillips, J. Frater, SPARTAC and CHERUB Investigators
United Kingdom

HIV Cure research in a novel population of South African hyper-acute HIV infections detected in the blood donation setting: the Monitoring and Acute Treatment of HIV Study (MATHS)

K. van den Berg, M. Vermeulen, T. Xulu, C. McClure, C. Ingram, G. Beck, M. Stone, M.P. Busch, B. Custer, E.L. Murphy, NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)
South Africa

WEBS01 Nurses at the Forefront: The Key to Achieving 90-90-90

Bridging Session

Venue: Session Room 12

Time: 11:00-12:30

Co-Chairs: Susan Michaels-Strasser, ICAP at Columbia University, United States
Simon Hlungwani, Democratic Nursing Organization of South Africa, South Africa

Nurses are at the frontline of the HIV response and continue to be paramount in successful implementation of increasingly nuanced efforts towards epidemic control. Implementation of the 2015 WHO Consolidated Guidelines will require that nurses play a central role in treating more people with higher quality care. This session highlights the science behind Test and Start, the importance of nurses' role in leadership and community responsiveness towards 90-90-90, and analyses current challenges and opportunities. It is directed towards nurses, policy makers, implementers, educators and community members.

Introduction

The science behind test and start and nursing role in achieving universal access

S.Michaels-Strasser, ICAP at Columbia University, United States

The role of nursing leaders in epidemic control: lessons learned from HIV service scale up in South Africa

N.Makhanya, National Department of Health, South Africa

Questions and answers

Advancing HIV nursing practice: lessons learned and future goals from nursing leadership and advocacy

C.Treston, Association of Nurses in AIDS Care, United States

Advancing HIV nursing practice in the community - practice challenges and opportunities: the perspectives of a rural Kenya NIMART nurse

L.Kosgei, Ministry of Health, Kenya

Questions and answers

Discussion and concluding remarks

WESY01 Optimizing the HIV Care Continuum Through Implementation Science Research

Symposia Session

Venue: Session Room 2

Time: 11:00-12:30

Co-Chairs: Velephi Okello, Ministry of Health, Swaziland
Jean B. Nachega, Johns Hopkins University, United States

Implementation science has garnered much attention as recent experience has demonstrated that there is an urgent need for defining the "how"—how to deliver efficacious interventions and how to achieve programmatic effectiveness. This session highlights recent data, future direction for implementation science research, and provides analysis of illustrative implementation science studies. It offers an overview of how to assess the effectiveness of interventions aimed at overcoming barriers to improve health outcomes and how to enhance the delivery of HIV prevention, care and treatment and related health services. The session is directed towards clinicians and staff engaged in HIV programme, programme managers, and researchers interested in implementation science. At the completion of the session, participants will understand key implementation science concepts, why such research is needed and the design principles of implementation science studies. They will also comprehend the specific challenges of implementation science research.

Introduction

Implementation science: what is it and what can it teach us?

D.Castor, United States Agency for International Development (USAID), United States

Utilizing implementation science to address barriers along the HIV care continuum

R.Barnabas, University of Washington, United States

Adapting global and national guidelines in a large implementation science study HPTN 071 (PopART)

R.Hayes, London School of Hygiene & Tropical Medicine, United Kingdom

HIV/AIDS implementation science research in Canada

J.Philpott, Health Canada, Canada

Panel discussion and Q&A

WESY02 UNGASS 2016: HIV/AIDS and Unsafe Drug Use: Public Health and International Drug Policy

Symposia Session

Venue: Session Room 5

Time: 11:00-12:30



Co-Chairs: Ruth Dreifuss, Former President, Switzerland
Quarraisha Abdoal Karim, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

This session addresses the shortcomings in the response to HIV and hepatitis C among people who use drugs. The 2015 target of the 2011 UN Political Declaration on HIV/AIDS of halving the transmission of HIV among injecting drug users has not been reached. In Eastern Europe and many parts of Asia, unsafe drug injection continues to fuel the HIV epidemic. The issue of drug abuse and HIV related to drug use is of growing concern in Africa. The session is targeted towards local and regional policy makers, researchers and advocates explaining the need to reform national drug policies, and to deliver the health, HIV and social services to people who use drugs. Participants will develop an understanding of the links between the scale up of harm reduction, the decriminalization of drug use, the end of incarceration for users, and the positive outcomes on the health and human rights of all.

Introduction

The findings of the Johns Hopkins-Lancet Commission on Public Health and International Drug Policy

A.Kamarulzaman, University of Malaya, Malaysia

Drug use and harm reduction in Africa: a 2016 perspective

I.Obot, Centre for Research and Information on Substance Abuse, Nigeria

The HIV epidemic among people who inject drugs in Eastern Europe

M.Kazatchkine, UN Secretary-General Special Envoy on HIV/AIDS in Eastern Europe and Central Asia, Switzerland

Harm reduction: HIV and criminalization of drug use in Asia

A.Fordham, International Drug Policy Consortium, Thailand

Moderated discussion

Conclusion

WESY03 Opportunities for and Challenges to Sustainable Financing of the AIDS Response

Symposia Session

Venue: Session Room 11

Time: 11:00-12:30

Co-Chairs: Mark Dybul, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland
Jimmy Kolker, U.S. Department of Health and Human Services (HHS), United States

Predictable and sustainable financing of the AIDS response is critical to achieving the Sustainable Development Goals. HIV financing is currently characterised by high donor dependency and uncertainty about future international assistance. This session addresses the critical importance of sustainable financing for the AIDS response moving towards 2030 and beyond and focuses on three critical components of sustainable financing: (1) fully funding the Global Fund; (2) transitions in middle-income status and (3) innovations and leveraging resources from non-traditional sources, including the private sector.

The session is targeted towards policy and decision makers, HIV advocates and activists and will provoke discussion on different aspects of sustainably financing of the AIDS response. Participants will gain an understanding of the key elements of sustainable HIV financing and their importance for the efforts in achieving the 2030 targets.

Introduction

Opening remarks

M.Dybul, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland

Fully funding the Fund

C.Stegling, International HIV/AIDS Alliance, United Kingdom

Eligibility and transitioning: the impact on the AIDS response

V.Zhovtyak, East Europe and Central Asia Union of PLWH, Ukraine

Options for innovative funding and leveraging resources from non-traditional funding sources

P.Douste-Blazy, Special Advisor to the United Nations Secretary-General on Innovative Finance for Development, France

Moderated discussion

Conclusion

WEWS02 Innovations in Testing and Approaches

Scientific Workshop

Venue: Session Room 9

Time: 11:00-12:30

Level: Advanced

Target audience: Healthcare worker / Social Services worker / Laboratory technician, Policy / Administration, Programme implementation specialist

Seating limit: 300

Co-Facilitators: Robert Matiru, UNITAID, Switzerland
Dorothy Mbori-Ngacha, UNICEF, Nigeria
Rachel Baggaley, World Health Organization (WHO), Switzerland
Badara Samb, UNAIDS, Switzerland
John Nkengasong, Centers for Disease Control (CDC), United States

The world is focused on the new ambitious UNAIDS treatment targets of "90-90-90" by 2020, but only 51% of people living with HIV know their status, indicating major challenges remain to dramatically improve HIV testing and access. Reaching these targets will require a massive expansion of HIV diagnostics and services to both ascertain HIV status for the majority of the population and monitor the viral load of those initiated and continuing on antiretroviral treatment. Countries- should consider simplification of testing approaches (self-testing, home based testing or testing using community outreach) and strategic decentralization of conventional laboratory-based technologies, using quality assured innovative point of care (POC) technologies; while improving laboratory efficiency, supervisory role and strengthening national diagnostic network. Aware of the current gaps, this workshop aims to provide the key considerations needed in translating the POC technologies and testing approaches to make the impact in the field.

Welcome and opening remarks

R.Matiru, UNITAID, Switzerland

Case presentation on key considerations for Point Of Care testing and country readiness

D.Mbori-Ngacha, UNICEF, Nigeria

Operational guidance of innovations in scaling up HIV testing and approaches

R.Baggaley, World Health Organization (WHO), Switzerland

Conclusion

R.Baggaley, World Health Organization (WHO), Switzerland;
J.Nkengasong, Centers for Disease Control (CDC), United States;
B.Samb, UNAIDS, Switzerland

WEWS03 Reaching the Unreached: Service Uptake and Retention Among Marginalized Populations

Scientific Workshop

Venue: Session Room 10

Time: 11:00-12:30

Level: Advanced

Target audience: Policy-maker, Community health worker, Community-based researcher

300



Seating limit:

Co-Facilitators: Tarandeep Anand, The Thai Red Cross AIDS Research Centre, Thailand
Zoe Duby, Desmond Tutu HIV Centre, South Africa
Ingrid Katz, Brigham and Women's Hospital, Harvard Medical School, United States

Many sub-populations from low- to high-income settings are unable to access adequate HIV testing and treatment programmes. For certain key populations, these services either do not exist or are not easily accessible due to stigma and criminalization. These high-risk individuals are not being reached by prevention and care messaging, choose not to access services for a variety of reasons, or are being lost even after they enter the treatment cascade. There is a persistent mismatch between national programme messaging and the delivery of services to those most at risk of HIV infection (e.g. resources for school-based prevention instead of support for people who inject drugs). The workshop presents examples of successful programmes for access and service delivery that have been able to reach these unreached populations.

Introduction

C.Orrell, University of Cape Town, South Africa

Understanding the underserved: minorities within the majority

I.Katz, Brigham and Women's Hospital, Harvard Medical School, United States

Novel Online-to-Offline (O2O) model to optimize HIV prevention to care cascade

T.Anand, The Thai Red Cross AIDS Research Centre, Thailand

Key population sensitization training for health care workers in South Africa: successes, challenges, lessons learned, and ways forward

Z.Duby, Desmond Tutu HIV Centre, South Africa

Questions and answers

Conclusions and discussion

WEWS04 Measuring Antiretroviral Therapy Adherence: Using Real-Time Adherence Monitoring in Research and Practice

Scientific Workshop

Venue: Session Room 13

Time: 11:00-12:30

Level: Foundation

Target audience: Social or behavioural science researcher, Implementation science researcher, Community-based researcher

Seating limit: 180

Co-Facilitators: Reuben Robbins, Columbia University, United States
Claude Ann Mellins, Columbia University, United States
Robert H. Remien, Columbia University, United States
Lloyd Marshall, Wisepill Technologies, South Africa

Electronic monitoring devices that assess adherence to medications in real-time are currently considered one of the most objective measures of adherence. One of these devices, Wisepill, is a small pill container, that records the date and time the device is opened and sends those event details to a server in real-time, monitoring whether pills are taken at the appropriate time(s) per day. Wisepill has been primarily used in research contexts with HIV in low-resource settings, but has potential for wider implementation. Participants attending this workshop learn how to set-up Wisepill for clinical and/or research use, how to use the Wisepill website, how to troubleshoot the Wisepill barriers for patients in low-resource contexts, how to manage and tailor the data outputs to specific contexts and how to use Wisepill as an intervention tool. The role of alternate adherence measurement tools in combination

with Wisepill is also discussed.

Introduction

R.Robbins, Columbia University, United States

Overview of Wisepill

Examples of Wisepill use in research

Wisepill demonstration

Participant engagement

Closing remarks

WEWS01 Advocacy Tactics I: High Level Meetings, Sustainable Development Goals, and Grassroots Activism

Leadership Workshop

Venue: Session Room 3

Time: 11:00-12:30

Level: Advanced

Target audience: Activist / Advocate

Seating limit: 300

Co-Facilitators: Anele Yawa, Treatment Action Campaign (TAC), South Africa
Bactrin Killingo, International Treatment Preparedness Coalition (ITPC), Kenya
Alessandra Nilo, Gestos, Brazil
Maria Lourdes Marin, 7 Sisters, Thailand

While governments and international bodies negotiate the language of "ending AIDS," people living with HIV, key populations, and activists on the ground continue their struggles for access to health care – including treatment access – and for human rights protections. In this workshop, activists from three continents share successful advocacy tactics in accelerating treatment access, reducing drug stock outs, fighting for sexual and reproductive health and rights, and ensuring meaningful participation of civil society. Speakers report back from the 2016 High Level Meetings (HLM) on HIV and AIDS and the 2030 Agenda for Sustainable Development. Through interactive dialogues and trainings, participants leave with an understanding of how to use the HLM Political Declaration and the Sustainable Development Goals (SDGs) in advocacy.

Welcome and introduction

C.Collins, UNAIDS, Switzerland; L.Sprague, HIV Justice Network, United States

TAC stock out campaign

A.Yawa, Treatment Action Campaign (TAC), South Africa

Treatment advocacy

B.Killingo, International Treatment Preparedness Coalition (ITPC), Kenya

UNGASS AIDS Forum Experience leading to the SDGs

A.Nilo, Gestos, Brazil

Cross-movement collaboration and the HIV Response

M.Marin, 7 Sisters, Thailand

Questions and answers

Group discussion

Closing remarks

C.Collins, UNAIDS, Switzerland; L.Sprague, HIV Justice Network, United States

WEPDE01 Filling the Gaps in PMTCT/B+ Programmes

Oral Poster Discussion Session

Venue: Session Room 3



Time: 13:00-14:00

Co-Chairs: Landry Tsague, UNICEF, Senegal
Dhayendre Moodley, University of KwaZulu Natal, South Africa

Virologic outcomes among women initiating antiretroviral therapy through the Option B+ program in Malawi: 6 month results from the PURE study

M. Hosseinipour, C. Trapence, C. Stanley, F. Kasende, B. Kaunda-Khangamwa, V. Kayoyo, M. van Lettow, N. Rosenberg, H. Tweya, V. Sampathkumar, E. Schouten, A. Kapito-Tembo, F. Cataldo, L. Chiwaula, S. Phiri, PURE Consortium Malawi Malawi

Counselled to compliance: experiences of Option B+ for the prevention of mother to child transmission in four health and demographic surveillance sites in sub-Saharan Africa

E. McLean, J. Renju, J. Wamoyi, D. Bukenya, W. Ddaaki, K. Church, A. Wringe, ALPHA Network United Kingdom

MomConnect: MHealth strengthening of demand and supply sides of the South African health system to improve PMTCT

P. Barron, Y. Pillay, J. Sebidi, A. Fernandes South Africa

Viral load sample logistics for HIV-positive women in rural settings: experience from the INSPIRE MoMent Nigeria PMTCT study

O. Adeyemi, S. Ereka, E. Ogum, F. Yunusa, H. Swomen, A. Barde, C. Chime, I. Ebagua, N.A. Sam-Agudu Nigeria

Early retention in antenatal care among HIV-positive women enrolled in the Option B+ program in Kinshasa, DRC

J. Ditekemena Dinanga, M.M. Gill, A. Loando, C. Nyombe, J. Bakwalufu, N. Mbonze, F. Fwamba, V. Ilunga, R. Machezano Congo, Democratic Republic of the

Self-reported antenatal adherence to predict postnatal viral rebound among women initiating ART during pregnancy in Cape Town, South Africa: a prospective study

T. Phillips, K. Brittain, E.J. Abrams, A. Zerbe, A. Ronan, C.A. Mellins, R.H. Remien South Africa

Moderated discussion

WEPDC01 Circumcision: Where to, How to, Who to?

Oral Poster Discussion Session

Venue: Session Room 5

Time: 13:00-14:00

Co-Chairs: Emmanuel Njeuhmeli, United States Agency for International Development (USAID), United States
Catherine Hankins, The Amsterdam Institute for Global Health and Development (AIGHD), Netherlands

Circumcision and vaccination programmes

E. Njeuhmeli, United States Agency for International Development (USAID), United States

Evaluation of the AccuCirc device for early infant male circumcision in Kisumu, Kenya: uptake and safety

I. Nyaboke, V. Pengo, S. Ojuok, M. Athiambo, E. Okello, F. Otieno, R. Plank, R.C. Bailey Kenya

The interaction of low male circumcision and high partner concurrency on HIV risk in Africa: evidence from demographic and health surveys

M. Little, A. Fox United States

Barriers to and facilitators of VMMC uptake among older men aged 25-39 years in Nyanza Region, western Kenya: the TASC0 study

K. Agot, J. Grun, E. Mboya, P. Musingila, E. Omanga, D. Emusu, E. Odoyo-June, S. Ohaga, B. Otieno-Nyunya United States

Safety of the no-flip technique and spontaneous detachment for ShangRing circumcision in boys and men: results from a randomised controlled trial

Q.D. Awori, R. Lee, P. Li, D. Ouma, N. Obura, M. Oundo, D. Mwamkita, B. Chirchir, M. Barasa, M. Kirul, P. Macharia, J. Oketch, P. Otiende, N. Nyangweso, M. Maina, N. Kiswi, M. Goldstein, J. Nyanchoka, M.A. Barone Kenya

Adolescent girls' support of male peers and sexual partners receiving voluntary medical male circumcision services: implications for demand creation

M. Kaufman, K. Dam, K. Hatzold, L. Van Lith, G. Ncube, G. Lija, C. Bonnecwe, W. Mavhu, C. Kahabuka, K. Seifert-Ahanda, A. Marcell, L. Mahlasela, M.E. Figueroa, E. Njeuhmeli, A. Tobian, Adolescent VMMC Technical Advisory Group United States

Safety of a facility-based versus community-based model of early infant male circumcision using the Mogen clamp in western Kenya: Mtoto Msafi Mbili Study

E. Adera, M. Young, T. Adipo, F. Otieno, S. Nordstrom, S. Mehta, R.C. Bailey Kenya

Moderated discussion

WEPDB01 Living with HIV: Long-Term Effects

Oral Poster Discussion Session

Venue: Session Room 7

Time: 13:00-14:00

Co-Chairs: Kevin Brian Rebe, ANOVA Health Institute, South Africa
Adeeba Kamarulzaman, University of Malaya, Malaysia

Deferred antiretroviral therapy is associated with lower estimated glomerular filtration rate in HIV-positive individuals with high CD4 counts

A. Mocroft, A.C. Achra, M. Ross, L. Ryom, A. Avihingsanon, E. Bakowska, W. Belloso, A. Clarke, H. Furrer, G. Lucas, M. Ristola, M.S. Rasso, J. Ross, C. Somboonwit, C. Wyatt, On behalf of the INSIGHT and START Study Group United Kingdom

The effect of HIV infection on the age at presentation of HBV-driven hepatocellular carcinoma in South Africa

T. Maponga, H. Vermeulen, B. Robertson, S. Burmeister, W. Preiser, M. Kew, M. Andersson South Africa

Antiretroviral treatment adherence, viremia, and psychiatric diagnosis throughout adolescence among perinatally HIV-infected youth

A. Bucek, C.-S. Leu, S. Benson, P. Warne, E. Abrams, K.S. Elkington, C. Dolezal, A. Wiznia, C.A. Mellins United States

HIV associated neurocognitive disorder in a peri-urban HIV clinic in KwaZulu-Natal, South Africa

J.C. Mogambery, H. Dawood, D. Wilson, A. Moodley South Africa

Ageing and associated morbidity in HIV-positive persons in the Cohort of the Spanish AIDS Research Network (CoRIS)

B. Alejos, V. Hernando, J. del Amo, R. Rubio, M. Montero, M. Rivero, J. Hernández-Quero, R. Muga, F. Gutierrez, S. Moreno, CoRIS Spain

Low rates of cholesterol screening despite cardiovascular risk in protease inhibitor-treated HIV patients in Botswana

M. Mosepele, L. Mokgathe, P.F. Hudson, V. Letsatsi, R. Gross Botswana

Moderated discussion

WEPDC02 Prevention for Women: The Need for Multidisciplinary Approaches

Oral Poster Discussion Session

Venue: Session Room 8

Time: 13:00-14:00

Co-Chairs: Dazon Dixon Diallo, SisterLove, Inc., United States
Loyce Maturu, Africaid Zvandiri, Zimbabwe



Vaginal bacteria associated with increased risk of HIV acquisition in African women

R.S. McClelland, J.R. Lingappa, G. John-Stewart, J. Kinuthia, K. Yuhas, W. Jaoko, S. Srinivasan, K.N. Mandaliya, T.L. Fiedler, M.M. Munch, B.A. Richardson, J. Overbaugh, D.N. Fredricks
United States

A brief, trauma-informed intervention is feasible and acceptable, increases safety behaviour, and reduces HIV risk among drug-involved women who trade sex

M. Decker, C. Tomko, E. Wingo, S. Peitzmeier, A. Sawyer, N. Glass, S. Sherman, A. Wirtz
United States

HIV pre-exposure prophylaxis (PrEP) formulation preference among women participating in the qualitative component of the ASPIRE (MTN-020) study

A. van der Straten, M.K. Shapley-Quinn, K. Reddy, H. Cheng, J. Etima, K. Woeber, P. Musara, T. Palanee-Phillips, J. Baeten, E.T. Montgomery, MTN-020/ASPIRE Study Team
United States

Sexual behaviour of men and women within age-disparate partnerships in South Africa: implications for young women's HIV risk

B. Maughan-Brown, M. Evans, G. George
South Africa

Evidence for selection effect and Hawthorne effect in behavioural HIV prevention trial among young women in rural South Africa

M. Rosenberg, A. Pettifor, R. Twine, J. Hughes, F.X. Gomez-Olive, R.G. Wagner, A. Selin, C. MacPhail, K. Kahn
United States

Adherence to topical PrEP: qualitative findings from the FACTS 001 trial

J. Stadler, S. Delany-Moretlwe, D. Baron, S. Ju, G. Gray, H. Rees, FACTS 001 Study Group
South Africa

Moderated discussion

WEPDD01 Translating Tradition in the AIDS Response

Oral Poster Discussion Session

Venue: Session Room 9

Time: 13:00-14:00

Co-Chairs: Francis Mangani, Embassy of Sweden, Zambia
Luann Hatane, PATA, South Africa

Promise or Peril? The nature of medical pluralism along the cascade of care for HIV/AIDS in eastern and southern Africa

M. Moshabela, D. Bukonya, G. Darong, J. Wamoyi, T. Zuma, J. Renju, C. Nyamukapa, W. Ddaaki, O. Bonnington, J. Seeley, V. Hoosegood, A. Wringe
South Africa

Claims of a cure: use of CD4 cell count results to guide traditional treatment in Bushbuckridge, South Africa

C. Audet, S. Ngobeni, R. Wagner
United States

Moonlight methadone for Muslims on medically assisted therapy curbing drug relapse in Malindi, Kenya

S. Abdallah, F. Ibrahim, M. Kirimo, A. Mongi, J. Baya, M. Shossi, A. Omar
UNODC

Taking on faith: a narrative analysis of discussions about HIV used by participants platforms for contesting faith in 9 high HIV-burden communities in the Western Cape, South Africa

S. Nomsenge, A. Thomas, G. Hoddinott, G. Carolus, V. Bond, On behalf of HPTN 071 (PopART) Study Team
South Africa

Capacity building of traditional health practitioners to mainstream HIV and AIDS prevention in Zimbabwe

F. Dube, M. Dube, A. Mpofo, T. Magure, I. Taramusi
Zimbabwe

Developing an ethical indigenous research protocol: sowing seeds for the inclusion of indigenous peoples with HIV

C.D.P. Montalvo Pacahuala, T. Stratton, R. Masching, A. King, C. Aspin

Peru

Moderated discussion

WEPDA01 Intrinsic and Adaptive Immunity

Oral Poster Discussion Session

Venue: Session Room 10

Time: 13:00-14:00

Co-Chairs: Jaclyn Mann, University of KwaZulu-Natal, South Africa
Jessica Taaffe, Global Renaissance Enterprises, United States

Novel mode of recognition of the glycan-V1V2 region of HIV-1 envelope by a new lineage of broadly neutralizing antibodies

E. Cale, J. Gorman, N. Radakovich, G. Ozorowski, E. Crooks, K. Osawa, M. Asokan, N. Doria-Rose, A. Ward, P. Kwong, J. Binley, J. Mascola
United States

Non-classical CD8+ T cells restricted by HLA class II emerge in HIV infection and show antiviral efficacy

S. Ranasinghe, P. Lamothe-Molina, D. Soghoian, S. Kaizer, M. Cole, A. Shalek, N. Yosef, B. Jones, M. Carrington, H. Streeck, D. Kaufmann, L. Picker, J. Kappler, B.D. Walker
United States

Presence of HIV-1C broadly neutralizing antibodies in pregnancy and at delivery

T. Mduluzi, S. Dzoro, K. Bedi, W.S. Mpoloka
Zimbabwe

PML/TRIM19-dependent inhibition of retroviral reverse-transcription by Daxx

J. Dutrieux, G. Maarifi, D. Portilho, N. Arhel, M. Chelbi-Alix, S. Nisole
France

Human sPD1-based HIV-1 gag-fusion DNA vaccine induces high frequency of broadly reactive T cell responses in mice and rhesus macaques

S. Chen, J. Tang, Z. Chen
Hong Kong, SAR of China

Moderated discussion

WEPDE02 It Takes a Community: Leadership, Engagement and Innovation

Oral Poster Discussion Session

Venue: Session Room 13

Time: 13:00-14:00

Co-Chairs: Ken Morrison, Palladium Group, Mexico
Loretta Wong, AIDS Healthcare Foundation, United States

Community leader engagement and peer group attendance improves selected MCH and PMTCT services uptake and retention: preliminary findings from project ACCLAIM

G. Woelk, M.P. Kieffer, D. Mpofo, R. Cathcart, ACCLAIM Study Group
United States

The importance of involving young women living with HIV in sexual reproductive health research: International Community of Women Living with HIV Eastern Africa (ICWEA) experience

B. Azizuyo
Uganda

"When you don't have money, he controls you": financial security, community savings groups, and HIV risk among female sex workers in Iringa, Tanzania

A. Mantsios, C. Shembilu, J. Mbwambo, S. Likindikoki, S. Beckham, A. Mwampashi, A. Leddy, N. Galai, W. Davis, D. Kerrigan
United States

Chasing the possible: are we there yet? Innovations in testing to end the HIV epidemic in NSW, Australia

T. Duck, C. Selvey, B. Telfer, H.M.A. Schmidt, K. Price, P. Keen, M.E. Cecilio, J. Holden
Australia



A cohort study of community-based test and treat for men who have sex with men and transgender women: preliminary findings from Thailand

R. Vannakit, J. Jantarapakde, S. Pengnonyang, S. Jitjang, R. Janamnuysook, T. Pankam, D. Trachunthong, K. Pussadee, R. Reankhomfu, D. Lingjongrat, S. Janyam, T. Nakpor, P. Leenasirimakul, T. Jadwattanakul, S. Noriega, S. Charoenying, T. Sattayapanich, A. Arunmanakul, P. Phanuphak, M. Cassell, N. Phanuphak
Thailand

Moderated discussion

WEWS01 Accelerating the Decline of the Burden and Incidence of HIV in Sub-Saharan Africa

Special Session

Venue: Session Room 1

Time: 13:00-14:00

Chair: Salim Abdool Karim, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

This session features a moderated dialogue about progress to date and challenges ahead in the HIV response in Sub-Saharan Africa. Bill Gates will join a panel of national leaders for a discussion on sustaining and accelerating the delivery of existing treatment and prevention tools, and the critical need for continued innovation.

Introduction

Address

B. Gates, Bill & Melinda Gates Foundation, United States

Moderated discussion

B. Gates, Bill & Melinda Gates Foundation, United States; L. Bekker, Desmond Tutu HIV Centre, South Africa; N. Kilonzo, National AIDS Control Council of Kenya, Kenya

Questions and answers

Closing remarks

WEWS09 Curbing Unmerited Patents and High Prices in Middle Income Countries

Community Workshop

Venue: Session Room 8

Time: 14:30-17:00

Level: Intermediate

Target audience: Advocate, Activist, Policy-maker

Seating limit: 500

Co-Facilitators: Tahir Amin, Initiative for Medicines, Access, & Knowledge (I-MAK), United States
Othoman Mellouk, International Treatment Preparedness Coalition (ITPC MENA), Morocco
Priti Radhakrishnan, Initiative for Medicines, Access, & Knowledge (I-MAK), United States
Kajal Bhardwaj, Independent Lawyer, India

Middle income countries (MICs) pay high prices for antiretrovirals (ARVs), hampering their ability to close the treatment gap and to adopt newer ARVs in their treatment protocols. Patent monopolies and exclusion from pharmaceutical companies' access initiatives and voluntary licenses contribute to these high prices. Companies file more patents in MICs and many of these are unmerited covering only minor modifications of known substances. This leads to abusive patent protection, which blocks generic competition that could lead to dramatically lower prices. This workshop aims to build the capacity and provide support to civil society advocates and organizations seeking to instill stricter patent examination standards and engage in patent opposition strategies. Using the experience of the facilitators, the workshop provides practical guidelines and examples for setting stricter

patentability standards and strategies for filing patent oppositions including conducting patent searches, monitoring patent applications, prior art search and drafting of oppositions.

Introduction and welcome

O. Mellouk, International Treatment Preparedness Coalition (ITPC MENA), Morocco

Strict patentability criteria and your patent law

K. Bhardwaj, Independent Lawyer, India

Engaging with patent offices

P. Radhakrishnan, Initiative for Medicines, Access, & Knowledge (I-MAK), United States

Group Work

Working on patent oppositions

T. Amin, Initiative for Medicines, Access, & Knowledge (I-MAK), United States

Interventions on patent oppositions: global experiences and national experiences (Ukraine, Argentina, India)

Open house discussion

WEWS10 Addressing the Specific Needs of Women Who Inject Drugs

Community Workshop

Venue: Session Room 9

Time: 14:30-17:00

Level: Intermediate

Target audience: Community health worker, Advocate, Skills building trainer

Seating limit: 300

Co-Facilitators: Monica Ciupagea, UNODC, Austria
Ruth Birgin, International Network of Women Who Use Drugs (INWUD), Australia
Judy Chang, Women and Harm Reduction International Network (WHRIN), United Kingdom
Olga Belyaeva, Eurasian Harm Reduction Network (EHRN), Lithuania
Monica Beg, UNODC, Austria

Women who inject drugs (WID) face a range of gender-specific barriers to accessing HIV-related services and remain a particularly hard-to-reach population, even where harm reduction programs are in place. The stigma and discrimination that they experience, which is often heightened by gender-based violence and abuse, increases their risk of contracting HIV, other blood-borne viruses. Often, harm reduction projects may not be able to guarantee WID personal safety and confidentiality and do not provide sexual and reproductive health services, prevention of mother-to-child transmission (PMTCT) services, or child care. This workshop uses existing success stories to build the capacity of the participants to mainstream gender into services for people who inject drugs. It provides guidance on HIV programming for women who inject drugs.

Welcome and introduction

Reconsidering risk game: What makes women who inject drugs 'hard-to-reach?'

What is the role for women who inject drugs community based organisations in the AIDS response?

R. Birgin, International Network of Women Who Use Drugs (INWUD), Australia

Women and Harm Reduction International Network (WHRIN)

J. Chang, Women and Harm Reduction International Network (WHRIN), United Kingdom

Eurasian Harm Reduction Network (EHRN)

O. Belyaeva, Eurasian Harm Reduction Network (EHRN), Lithuania

Questions and answers



Assessing capacity to meet women who inject drugs needs: interactive exercise and paired-sharing of experience

Case studies: identifying barriers of service in participants countries

Brainstorming for potential solutions to key barriers

Lessons for success: report back of findings on barriers and solutions

International standards and statements that can assist harm reduction service providers in developing women who inject drugs services

Evaluation and closing remarks

WEAB02 Taking TB from Testing to Treatment

Oral Abstract Session

Venue: Session Room 1

Time: 14:30-16:00

Co-Chairs: Shannon Hader, Centers for Disease Control and Prevention, United States
Tendani Gaolathe, Botswana Harvard Partnership, Botswana

Daily is better than thrice-weekly anti-tuberculosis therapy in HIV patients with culture confirmed pulmonary TB: a randomised controlled clinical trial from south India

N. Gopalan, S. Ramesh Kumar, C. Padmapriyadarsini, N.S. Gomathi, P.A. Menon, L. Sekar, S. Devarajulu Reddy, S. Chandra, A.K. Hemanth Kumar, S. Kumar, S. Sekar, N. Ravichandran, K. Raja, J. Lavanya, R. Sridhar, M. Lakshmi, A. Mahilmaran, S. Swaminathan
India

Intensified tuberculosis case-finding among people living with HIV: diagnostic yield of Xpert MTB/RIF, urine lipoarabinomannan and liquid culture

E. Atuhumuza, C. Yoon, J. Katende, L. Asege, S. Mwebe, A. Andama, D. Armstrong, D. Dowdy, M. Kamya, F.C. Semitala, A. Cattamanchi
Uganda

Cytomegalovirus viraemia and 12-week mortality among hospitalised adults with HIV-associated tuberculosis in Khayelitsha Hospital, South Africa: a prospective cohort study

A. Ward, D. Barr, C. Schutz, R. Burton, A. Boule, G. Maartens, R.J. Wilkinson, G. Meintjes
South Africa

Yield of community health worker-driven intensified case finding for tuberculosis among HIV-positive patients in rural Malawi

R. Flick, K. Simon, A. Munthali, A. Dimba, M. Kim, P. Kazembe, M. Hosseinipour, S. Ahmed
Malawi

High-dose rifampicin tuberculosis treatment regimen to reduce 12-month mortality of TB/HIV co-infected patients: the RAFA trial results

C.S. Merle, S. Floyd, A. Ndaye, T. Galperine, A. Furco, B.C. De Jong, H. McIlleron, J. Glynn, M. Sarr, O. Bah-sow, D. Affolabi, on behalf of the RAFA Team
WHO

Moderated discussion

WEAD01 It's All in the Family

Oral Abstract Session

Venue: Session Room 4

Time: 14:30-16:00

Co-Chairs: Heidi Van Rooyen, Human Sciences Research Council, South Africa
Sevgi Aral, Centers for Disease Control (CDC), United States

Sustained effect of couples' HIV counselling and testing on reducing unprotected sex among HIV serodiscordant couples

K. Wall, W. Kilembe, B. Vwalika, L. Haddad, N. Htee Khu, I. Brill, C. Vwalika, E. Chomba, A. Tichacek, S. Allen

United States

Positive impact of a randomized controlled trial of the Uthando Lwethu ("Our Love") intervention on rates of couples HIV testing in rural South Africa

L. Darbes, N.M. McGrath, M.O. Johnson, V. Hosegood, K. Fritz, T. Ngubane, H. van Rooyen
United States

Assessment of couple relationship quality and links to HIV prevention, treatment and care in rural Malawi

A. Ruark, D. Brewster-Lee, J. Hembling, V. Rhoe Davis
United States

Partner communication and support around HIV and how this relates to health-seeking behaviour: a qualitative study amongst HIV-positive individuals and couples in Karonga, Malawi

J. Renju, A. Wringe, A.C. Crampin, O. Koole, C. Nyirenda, H. Namadingo, E. McLean, ALPHA Network
United Kingdom

Intervention outcomes on mental health of PLH, family members and children: a randomized controlled trial in rural China

L. Li, L.-J. Liang, C.Q. Lin, Y. Xiao, G.P. Ji
United States

Moderated discussion

WEAC03 Adolescent Affairs

Oral Abstract Session

Venue: Session Room 5

Time: 14:30-16:00

Co-Chairs: Lisa Hightow-Weidman, UNC Chapel Hill, United States
Janan Dietrich, Perinatal HIV Research Unit, South Africa

The epidemiology of perinatally HIV-infected adolescents: a CIPHER cohort collaboration global analysis

A. Slogrove, A. Judd, V. Leroy, Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
South Africa

Prevalence and predictors of forced-sex among South African high school students

S. Naidoo, B. Sartorius, H. de Vries, M. Taylor
South Africa

The impact of a cash transfer on young South African women's on mental health: HPTN 068

A. Pettifor, J. Wang, A. Selin, J. Hughes, X. Gómez-Olivé, R. Wagner, C. MacPhail, K. Kahn, HPTN 068 Study Team
South Africa

Why the disparities? The first national look at HIV-related risk behaviours among gay and bisexual male high school students, United States 2015

L. Kann, E. Olsen, T. McManus, S. Zaza
United States

Changes in bone mass after discontinuation of PrEP with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in young men who have sex with men (YMSM): extension phase results of Adolescent Trials Network (ATN)110

K. Mulligan, S. Hosek, B.G. Kapogiannis, R.J. Landovitz, N. Liu, S.S. Cofield, S.E. Perumean-Chaney, P.L. Havens, B. Rutledge, C.M. Wilson, Adolescent Trials Network (ATN) for HIV/AIDS Interventions Protocol 110 Team
United States

Moderated discussion

WEAE02 Target 90-90-90: The Ups and the Downs

Oral Abstract Session

Venue: Session Room 12

Time: 14:30-16:00

Co-Chairs: Tsitsi Mutasa Apollo, Ministry of Health and Child Welfare, Zimbabwe
Velephi Okello, Ministry of Health, Swaziland

Current state of the global HIV care continuum

R. Granich, S. Gupta, I. Hall, J. Aberle-Grasse, S. Hader, J. Mermin

United States

Same-day HIV testing and antiretroviral therapy initiation results in higher rates of treatment initiation and retention in care

S. Koenig, N. Dorvil, P. Severe, C. Riviere, M. Faustin, C. Perodin, C. Paul, A. Apollon, G. Saintil, L. Duverger, E. Dumont, B. Hedt-Gauthier, K. Hennessy, V. Rivera, J. Devieux, J.W. Pape
United States

Towards the last 90% of the 90-90-90 strategy: a review of viral suppression rates in a HIV programme in central and eastern Kenya

M. Kithaka, K. Curran, P. Gathii, M. Mudany, S. Bii
Kenya

Eliminating CD4 thresholds in South Africa will not lead to large increases in persons receiving ART without further investment in testing, linkage and initiation

J. Bor, S. Ahmed, M.P. Fox, S. Rosen, I. Katz, F. Tanser, D. Pillay, T. Barnighausen
United States

First-year intervention outcomes of the Bukoba Tanzania combination prevention evaluation: promising HIV testing & linkage-to-care methods to achieve 90-90-90

D. MacKellar, H. Maruyama, R. Weber, O. Ernest, S. Porter, J. Gikaro, G. Alexander, G. Kundi, J. Byrd, K. Kazaura, D. Mbilinyi, F. Morales, J. Justman, R. Josiah
United States

LINK4HEALTH: a cluster-randomized controlled trial evaluating the effectiveness of a combination strategy for linkage to and retention in HIV care in Swaziland

M. McNairy, M. Lamb, A. Gachuhi, H. Nuwagaba-Biribonwoha, S. Burke, S. Mazibuko, V. Okello, P. Ehrenkranz, R. Sahabo, W. El-Sadr, Link4Health Study Group
United States

WEBS02 Game Changers in the HIV Response: Gay Dating Apps Join Efforts to End the Epidemic by 2030

Bridging Session

Venue: Session Room 2

Time: 14:30-16:00

Co-Chairs: Karl Dehne, UNAIDS, Switzerland
Patrick Sullivan, Emory University, United States

New information and communication technologies (ICT) are fast becoming an important source for enhancing the reach and effectiveness of HIV programmes among men who have sex with men (MSM). Dating application platforms are increasingly used to convey facts on prevention and promote access to services and some have also undertaken their own awareness campaigns to ensure the health and safety of their users. This session presents findings of a systematic review of evidence on the impact of such programmes on behaviours and service uptake, and provides a platform for discussions around utilizing dating apps as a tool for combination prevention. The session is targeted to policy makers, researchers and community representatives interested in the topic. At the completion of the session, participants will understand the emerging evidence around the use of ICT to reach MSM populations and will be able to identify good practices in health promotion through dating applications.

Introduction

K. Dehne, UNAIDS, Switzerland

Systematic review of evidence on the impact of programmes using new ICT on gay men's and other MSM' HIV-related behaviours and service uptake, and HIV work on online buddies

J. Rosenberger, Penn State University, United States

Grindr for equality: adapting apps for increased social consciousness around HIV

J. Harrison-Quintana, Grindr, United States

Promoting HIV prevention to 6 million users: Hornet joins efforts to eliminate stigma, educate and empower

S. Howell, Hornet, United States

An introduction to Danlan's HIV prevention programme

G. Le, Danlan, China

Questions and answers

Conclusions and way forward

WESY04 Getting to Scale: Examples of Success

Symposia Session

Venue: Session Room 6

Time: 14:30-16:00

Chair: Christine Stegling, International HIV/AIDS Alliance, United Kingdom

This session provides examples of how public health programmes accelerated the scaling up of prevention, treatment and anti-stigma programming. This session is targeted towards civil society advocates, government and business leaders. The audience will learn about successful examples that accelerated the delivery of critical services, and the challenges addressed along the way. There will be discussions of approaches that are working and not working, along with lessons learned.

Introduction

C. Stegling, International HIV/AIDS Alliance, United Kingdom

Examples from South Africa

A. Motsoaledi, Minister of Health, South Africa

Examples from the private sector

S. Nicolaou, Aspen Pharmacare, South Africa

Examples from the U.S.

J. Kolker, U.S. Department of Health and Human Services (HHS), United States

Examples from Thailand

S. Boonsuk, Ministry of Health, Thailand, Thailand

Interactive Panel Discussion

A. Motsoaledi, Minister of Health, South Africa; S. Nicolaou, Aspen Pharmacare, South Africa; J. Kolker, U.S. Department of Health and Human Services (HHS), United States; S. Boonsuk, Ministry of Health, Thailand, Thailand

Q&A

WESY05 Vulnerable Populations and HIV/AIDS in Islamic Communities

Symposia Session

Venue: Session Room 11

Time: 14:30-16:00

Co-Chairs: Arash Alaei, University at Albany, State University of New York, United States
Kamiar Alaei, State University of New York, University at Albany, United States

Many Islamic communities are currently facing a growing rate of HIV/AIDS that is not properly addressed at comprehensive epidemiological and service-based levels. Of greatest concern are vulnerable populations that face cultural, social, and political barriers which influence their HIV/AIDS services and that are often 'hidden' populations where no mechanisms exist to improve their access to acceptable HIV/AIDS services. Additionally, the number of wars occurring in the Middle East have prompted citizens to seek refuge from war-torn areas as immigrants or refugees making it ever important to discuss the trends of HIV/AIDS in traditionally vulnerable and underrepresented populations.

This session is targeted to health care workers, programme implementers, community workers and anyone involved or interested in the challenges faced by vulnerable populations in Islamic communities. Participants will gain an understanding of the key challenges faced by these groups in several national settings.

Introduction

MSM and HIV/AIDS in Turkey

S. Unal, Hacettepe University, Turkey

The perspective of religious leaders on vulnerable populations and HIV/AIDS

A.Alhamwi, Islamic University of Umdorman-Damascus, Syrian Arab Republic

HIV/AIDS in refugee and immigrant populations in Lebanon

J.Mokhbat, Lebanese Aids Society, Lebanon

Perspectives of HIV/AIDS from key populations

W.Jlassi, L'Association Tunisienne de Lutte, Tunisia

The stigmatization of women and HIV/AIDS in MENA

R.Wahab, Vivre Positif, Lebanon

Moderated discussion

Conclusion

WEWS07 Marketplace for Rings, Pills, Jabs and Other Things: Understanding New Biomedical Interventions to Reduce HIV Risk from Development to Delivery

Scientific Workshop

Venue: Session Room 3

Time: 14:30-17:00

Level: Foundation

Target audience: Advocate, Community-based journalist, Community health worker

Seating limit: 300

Co-Facilitators: Manju Chatani, AVAC, United States
Brian Kanyemba, Desmond Tutu HIV Centre, South Africa
Neetha Shagan Morar, Medical Research Council, South Africa

Clinical trials of biomedical HIV prevention candidates are conducted in many countries and in partnership with community, health professionals, advocates, policy makers and others. Success of trials and eventual implementation of efficacious interventions relies on the ability to inform and engage key stakeholders. This workshop provides basic information about clinical trials and the array of biomedical prevention interventions currently in various stages of development. It also addresses key issues for advocates and serves as an introduction or basic refresher for those who have limited or no knowledge of biomedical HIV prevention science.

Session objectives and welcome

B.Kanyemba, Desmond Tutu HIV Centre, South Africa

Understanding the clinical trials process

N.Shagan Morar, Medical Research Council, South Africa

HIV prevention research overview and the story of PrEP

M.Warren, AVAC, United States

HIV prevention research marketplace

Wrap-up and reflections

M.Chatani-Gada, AVAC, United States; A.Kaggwa-Katumba, AVAC, United States

WEWS08 PrEP Implementation: From Clinical Trials to Clinical Care

Scientific Workshop

Venue: Session Room 7

Time: 14:30-17:00

Level: Advanced

Target audience: Clinical scientist / Researcher, Public health official, Community health worker

Seating limit: 500 pax.

Co-Facilitators: Yogan Pillay, National Department of Health, South Africa
Jean-Michel Molina, University of Paris Diderot, France
Michael Kiragu, LVCT Health, Kenya

Iryna Zablotska, University of New South Wales (UNSW), Australia

Multiple studies have suggested that the use of tenofovir-emtricitabine can decrease HIV incidence, but only recently have local public health authorities implemented PrEP in clinical sites as part of an integrated HIV prevention package. This workshop shares best practices in PrEP provision from around the world, including case studies.

Welcome and introduction

H.Rees, University of Witwatersrand, South Africa; K.Mayer, Fenway Health, United States

PrEP rollout in Kenya

M.Kiragu, LVCT Health, Kenya

Strategic approaches of the South African government as it considers PrEP implementation

Y.Pillay, National Department of Health, South Africa

PrEP rollout in France

J.Molina, University of Paris Diderot, France

Expanded implementation of PrEP across Australia

I.Zablotska, University of New South Wales (UNSW), Australia

Interactive discussion

Conclusion and closing remarks

H.Rees, University of Witwatersrand, South Africa; K.Mayer, Fenway Health, United States

WEWS11 Quality Improvement Methods: How to Master the Run Chart

Scientific Workshop

Venue: Session Room 10

Time: 14:30-17:00

Level: Intermediate

Target audience: Programme implementation specialist, Public health official, Manager / Director

Seating limit: 300

Co-Facilitators: Gillian Dougherty, International Center for AIDS Care and Treatment Programs (ICAP), United States
Duncan Chege, ICAP at Columbia University, Kenya

This workshop focuses on one of the most commonly used Quality Improvement tools: the Run Chart. Following a presentation about the science of crafting and analyzing Run Charts, as well as an interactive discussion of participants' experience with the tool, workshop facilitators lead hands-on exercises designed to improve Run Chart development and analysis skills. Participants practice implementing and crafting Run Charts, and discuss the advantages of median lines, target lines, and annotation.

Welcome and Introduction

M.Rabkin, Columbia University, United States

Introduction to Run Charts (with hands-on participant exercise)

G.Dougherty, International Center for AIDS Care and Treatment Programs (ICAP), United States

Rules of Run Chart Analysis (with hands-on participant exercise)

D.Chege, ICAP at Columbia University, Kenya

Wrap up and conclusion

WEWS12 A Revolution Against Stigma! What Works to End HIV-related Stigma NOW!

Leadership Workshop

Venue: Session Room 13

Time: 14:30-17:00

Level: Intermediate

Target audience: Programme implementation specialist, Activist, Social or behavioural science researcher



Seating 180 limit:

Co-Facilitators: Laura Nyblade, RTI International, United States
Diego Luis Grajalez, Collaborative Network of Persons With HIV (C-NET+),
Jacquelyne Alesi, Uganda Network of Young People Living with HIV, Uganda
Fatou Maria Dramé, Gaston-Berger University; Enda sante, Senegal
Masimba Nyamucheta, The Zimbabwe Network of People Living with HIV (ZNNP+), Zimbabwe
Jane Ng'ang'a, International Network of Religious Leaders Living With or Personally Affected by HIV & AIDS (INERELA+), Kenya

HIV-related stigma and discrimination keep people from the prevention, treatment, care, and support services they need. However, we now have decades of experience implementing effective programmes to end stigma related to HIV and key population status. For recent biomedical advances to prevent new infections and keep people with HIV alive, we must commit to a revolution to end HIV-related stigma. This workshop is designed to share information about effective anti-stigma interventions and to allow participants the opportunity to work with global experts in different fields to develop an anti-stigma programme. The interventions to be highlighted focus on creating stigma-free health care settings, developing leadership and advocacy by people living with HIV, reducing internal or self-stigma among people living with HIV, ensuring equity in care for key populations, faith leaders building stigma free faith communities, and providing necessary psychosocial and mental health care for young people living with HIV.

Welcome and short film

L. Sprague, HIV Justice Network, United States

The current state of the field: stigma-reduction programming and measurement

L. Nyblade, RTI International, United States

The PLHIV Stigma Index and effective community organizing to end HIV prejudice and support key populations

D. Grajalez, Collaborative Network of Persons With HIV (C-NET+), Belize

Share good practices in mental health and psychosocial support to remove internalized stigma for young people living with HIV

J. Alesi, Uganda Network of Young People Living with HIV, Uganda

A multi-pronged anti-stigma approach to ensure equity in health care for key populations

F. Dramé, Gaston-Berger University; Enda sante, Senegal

Discussion of the process of and results from the community-based inquiry and stress reduction intervention to reduce self-stigma among people living with HIV

M. Nyamucheta, The Zimbabwe Network of People Living with HIV (ZNNP+), Zimbabwe

Using the Framework for Dialogue Programme to reduce HIV stigma in faith settings

J. Ng'ang'a, International Network of Religious Leaders Living With or Personally Affected by HIV & AIDS (INERELA+), Kenya

Questions and Answers

Group discussion

Closing remarks

L. Sprague, HIV Justice Network, United States

WEAB03 Bad Bugs, Better Drugs: Advances in Hepatitis and HIV Co-Infection Treatment

Oral Abstract Session

Venue: Session Room 1

Time: 16:30-18:00

Co-Chairs: Anchalee Avihingsanon, The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thailand
Jürgen K. Rockstroh, University of Bonn, Germany

Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase 3 ASTRAL-5 study

N. Bräu, D. Wyles, S. Kottitil, E. Darr, K. Workowski, A. Luetkemeyer, O. Adeyemi, P. Ruane, B. Doehle, K.C. Huang, A. Osinusi, J. McNally, M. Natha, M. Guion, T. McLean, D.M. Brainard, J.G. McHutchison, S. Naggie, M. Sulkowski
United States

Drug-drug interactions studies between HCV antivirals sofosbuvir and velpatasvir and HIV antiretrovirals

E. Mogalian, A. Luetkemeyer, S. Naik, M. Natha, L. Stamm, A. Osinusi, G. Shen, K. Sajwani, J. McNally, A. Mathias
United States

Higher mortality in HIV-HBV co-infected persons with elevated HBV replication in the Temprano Trial

M.G. Kouamé, R. Moh, A. Boyd, A. Badjé, D. Gabillard, J.B. N'takpé, S. Maylin, S.P. Eholié, X. Anglaret, C. Danel, ANRS12136 Temprano Trial Group
Cote d'Ivoire

TURQUOISE-I Part 2: safety and efficacy of ombitasvir + paritaprevir/r & #177; dasabuvir with or without RBV in patients with HIV-1 and HCV GT1 or GT4 co-infection

J.K. Rockstroh, C. Orkin, R.M. Viani, D. Wyles, A. Luetkemeyer, A. Lazzarin, R. Soto-Malave, M. Nelson, S.R. Bhagani, H.H.F. Klinker, G. Rizzardini, P.-M. Girard, N.S. Shulman, Y.B. Hu, L.M. Fredrick, R. Trinh, E. Gane
Germany

Hepatitis B viral load response to two antiviral regimens (tenofovir/lamivudine vs lamivudine) in HIV and HBV co-infected pregnant women in Guangxi, China: the Tenofovir in Pregnancy (TiP) Study

A. Kourtis, L. Wang, J. Wiener, S. Liang, X. Wei, W. Liu, L. Chen, C. Shepard, A. Wang, F. Zhang, M. Bulterys, TIP study Group
China

Moderated discussion

WEAC04 Alcohol, Substance Use and HIV

Oral Abstract Session

Venue: Session Room 2

Time: 16:30-18:00

Co-Chairs: Adeeba Kamarulzaman, University of Malaya, Malaysia
Frederick Altice, Yale University, United States

Long-term alcohol use patterns and HIV disease severity typologies in U.S. veterans: a joint trajectory analysis

B. Marshall, J. Tate, K. McGinnis, D. Fiellin, K. Bryant, A. Justice
United States

Extended-release naltrexone lengthens time to heavy drinking among HIV+ released prisoners with alcohol use disorders

S. Springer, M. Azar, R. Barbour, A. Krishnan, F. Altice, A. DiPaola
United States

Preliminary experience with medically assisted therapy for people who inject drugs in Mombasa County, Kenya

A.A. Baghazal, L. Tariko, K. Shikely, S. Patta, B. Omar, H. Musyoki, S. Bertrand, S. Abdallah
Kenya

Incarceration and people who inject drugs in Ukraine: modelling its role in HIV transmission and the impact of introducing OST in prisons

J. Stone, E. Brooks-Pollock, F.L. Altice, L. Azbel, P. Smyrnov, N.K. Martin, P. Vickerman
United Kingdom

Modelling the potential impact of the incarceration on HIV incidence among people who inject drugs in Tijuana, Mexico

A. Borquez, D. Abramovitz, L. Beletsky, P. Vickerman, P. Gonzales-Zuñiga, G. Rangel, M. Hickman, S.A. Strathdee, N. Martin
United States



Moderated discussion

WEAE03 Going Viral for Viral Load Implementation

Oral Abstract Session

Venue: Session Room 4

Time: 16:30-18:00

Co-Chairs: Trevor Peter, Clinton Health Access Initiative, Botswana
Shannon Hader, Centers for Disease Control and Prevention, United States

Implementation of routine viral load monitoring in Lesotho, Malawi, Mozambique and Zimbabwe: a cascade analysis

M. Dhodho, M. Frieden, A. Shroufi, E. Wanjiru, S. Daho, E. Simons, H. Bygrave
Zimbabwe

Viral load cascade and programmatic challenges after 2 years of routine HIV viral load testing in Maputo, Mozambique

R. Giuliani, A. Torrens, L. Molfino, C. Silva, T. Ellman, A. Magaia
Mozambique

Roll out of targeted viral load testing in two rural districts within Masvingo Province, Zimbabwe

J. van Dijk, K. Kamenova, A. Shamu, K. Pfeiffer, M. Hobbins, J. Ehmer, J. Murungu
Zimbabwe

Dried blood spots provide accurate enumeration of HIV-1 viral load in east Africa

R. Barnabas, R. Coombs, M. Chang, T. Schaafsma, S. Asimwe, K. Thomas, J. Baeten, C. Celum
United States

Monitoring of HIV-1 RNA with point-of-care cepheid Xpert HIV-1 viral load in rural African communities is feasible and reliable in the era of broad scale up of ART

S. Moyo, T. Mohammed, K. Wirth, K. Bennett, M.P. Holme, L. Mupfumi, P. Sebogodi, N.O. Moraka, C. Boleo, C.N. Maphorisa, B. Seraise, S. Gaseitsiwe, R.M. Musonda, E. van Widenfelt, K.M. Powis, T. Gaolathe, E.J. Tchetgen Tchetgen, J.M. Makhema, M. Essex, S. Lockman, V. Novitsky
Botswana

Using epidemiology and collaborative funding to enable innovation in opportunistic screening to reduce the late diagnosis of HIV: interim results from a targeted primary care project in England (UK)

O. Brigstock-Barron, L. Logan, H. Sowerbutts, V. Womack, M. Osman, J. Anderson, A. Nardone
United Kingdom

WEAD02 Sex through the Ages

Oral Abstract Session

Venue: Session Room 5

Time: 16:30-18:00

Co-Chairs: Martha Tholanah, Network of Zimbabwean Positive Women (NZPW+), Zimbabwe
Definate Nhamo, Pangaea Zimbabwe
AIDS Trust, Zimbabwe

Meeting the reproductive intentions of PLHIV in Malawi

L. Irani, E. McGinn, M. Mellish, O. Mtema, P. Dindi
Malawi

Sexual and reproductive health (SRH) needs and experiences of youth living with HIV

R. Imakit, S. Ajok, D. Talima, A. Namakula
Uganda

"I always wanted a big family because I lost mine": a qualitative analysis of parenting perspectives among young parents with perinatally-acquired HIV

H. Allen, C. Fair, C. Trexler, L. D'Angelo
United States

Biographies of HIV and cervical cancer: understanding treatment-seeking for cervical cancer amongst HIV-positive women in Inner City Johannesburg

J. Stadler, A. Chikandiwa, P. Mayaud, H. Rees, J. Imrie, S. Delany-Moretwe

South Africa

Findings from the Sexual Health and Aging Program (SHAPE) for older women with HIV pilot study and future directions

T. Taylor
United States

Moderated discussion

WEAD03 Pulling the Levers: Policy, Advocacy Approaches to Influence

Oral Abstract Session

Venue: Session Room 12

Time: 16:30-18:00

Co-Chairs: Alan Whiteside, Balsillie School of International Affairs, Canada
Sharonann Lynch, Doctors without Borders, United States

Measuring the impact of advocacy: civil society's influence over Global Fund concept notes in eight African countries

G. Oberth, O. Mumba, L. Bhayani
South Africa

Global solidarity to win increased accountability and impact from PEPFAR country programs: an analysis of north-south collaborative advocacy strategies

A. Russell, F. Mwanza, M. Milanga
Uganda

Demanding a high impact HIV response: civil society advocacy and the President's Emergency Plan for Aids Relief (PEPFAR) in Uganda

R. Nandelenga, D. Namutamba
Uganda

PLHIV in the Caribbean: many islands, same issues. Lack of resources, fragmented health/care systems: an under-resourced community response

C. Albert-Hope, R. Gustav, Y. Simon, E. Castellanos, R. Irwin
Trinidad and Tobago

Rapid response research to inform HIV policy decision-making: lessons learned from California's Collaborative HIV/AIDS Policy Research Centers

I.W. Holloway, W.T. Steward, J. Mortimer, P. Curtis, D. Van Gorder, A. Leibowitz, S. Morin, C. Mulhern-Pearson, A. Donnelly, A.J. King, A. Fox, C. Pulsipher, D. Evans, G. Lemp
United States

The uptake of population size estimation studies for key populations in guiding HIV responses across sub-Saharan Africa: a systematic review

S. Baral, C. Lyons, E. Sullivan, S. Kurani, J. Sherwood, G. Millett, J. MacAllister
United States

WEBS03 The Development and Pricing of HIV Medications and Diagnostics: Recent Controversies and Priorities for the Future

Bridging Session

Venue: Session Room 6

Time: 16:30-18:00

Chair: Nathan Ford, World Health Organization, Switzerland

This multi-perspective session takes stock of trends in the pricing of medications and diagnostics that are essential for the prevention and treatment of HIV and its comorbidities. As new treatment guidelines expand the number of individuals who need treatment and governments consider the costs of bolder responses to the epidemic, the prices of medicines and pharmaceuticals are likely to play an increasingly important role. The session discusses and analyses recent controversies over the pricing of medications and diagnostics, neglected areas in which greater development is needed, and policies that promote or hinder access. Directed towards policymakers, programme managers, advocates and community representatives, it also includes discussion of emerging issues and offers perspectives from the industry, donor organizations, and low- and middle-income countries. At the end of the session, participants will understand issues related to the pricing of pharmaceuticals and be able to

identify the various forces shaping prices.

Introduction

Recent trends in prices of antiretrovirals and diagnostics

S.Lynch, Doctors without Borders, United States

Role of national intellectual property laws and regulatory practices: examples from India, Brazil and South Africa

U.Rugege, Section 27, South Africa

Perspective from industry

A.Soni, Mylan, United States

Patents and access to medicines: a civil society perspective from eastern Europe

A.Klepikov, International HIV/AIDS Alliance, Ukraine

Questions and answers

Concluding remarks

N.Pandor, Minister of Science and Technology, South Africa

WESY06 Supporting HIV-affected Women and Men to Safely Meet Reproductive Goals: Insights into Contraception, Safer Conception, and Infertility

Symposia Session

Venue: Session Room 11

Time: 16:30-18:00

Co-Chairs: James Kiarie, World Health Organization (WHO), Switzerland
Renee Heffron, University of Washington, United States

This session addresses key emerging issues in contraception, safer conception, and infertility for women and men living with and exposed to HIV. Targeted towards policymakers, advocates and clinicians working in this field as well as people living with HIV interested in reproductive health issues, it aims to provoke discussion around new data and emerging challenges in providing these services. At the completion of the session, participants will have a thorough understanding of reproductive health choices and debates that women and men living with and affected by HIV and their providers grapple with in different HIV prevalence settings.

Introduction

R.Heffron, University of Washington, United States

Clinical issues and debates in contraception for women and adolescents exposed to HIV

J.Smit, University of the Witwatersrand, South Africa

Clinical issues and debates in contraception for women and adolescents living with HIV

A.Gray, University of KwaZulu-Natal, South Africa

Safer conception for men and women living with HIV and their partners: key issues and considerations for widespread implementation

N.Davies, Wits Reproductive Health and HIV Institute, South Africa

Prevalence, consequences and key issues in the management of infertility and subfertility among men and women living with HIV

J.Beyeza-Kashesya, Makerere University, Uganda

Community perspectives on reproductive health for HIV-affected populations

J.Wambui, National Empowerment Network of PLHIV in Kenya, Kenya

Questions and answers

Conclusion
